|
NVP-AUY922 biodistribution: pharmacokinetic parameters |
||||||
| Plasma |
Tumor |
Liver |
Muscle |
Heart |
Lung |
|
|
|
||||||
| Cmax, μmol/L or nmol/g |
14.08 ± 4.14 |
16.36 ± 3.84 |
30.94 ± 5.58 |
27.45 ± 6.64 |
36.86 ± 7.42 |
48.48 ± 10.11 |
| T 1/2 elimination λ_z, hours |
10.3 |
30 |
7.7 |
8 |
5.6 |
5.5 |
| AUC(0-8), hours* μmol/L or hours*nmol/g |
7.3 |
345 |
53 |
35 |
32 |
71 |
|
The concentration of NVP-AUY922 was determined by high-pressure liquid chromatography/tandem mass spectrometry after a single intravenous administration of 30 mg/kg to BT-474 tumor-bearing mice. The highest concentration (Cmax), terminal half-life (T 1/2 elimination λ_z), and exposure as determined by the area under the curve (AUC) were determined for each organ, plasma, and BT-474 xenograft (tumor). | ||||||
Jensen et al. Breast Cancer Research 2008 10:R33 doi:10.1186/bcr1996 |
||||||